Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
Do you recommend the use of Denosumab for osteoporosis management in patients receiving IVIG therapy?
Related Questions
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
How do you approach the frequency of DEXA scan monitoring for older adults on bisphosphonate therapy during the course of therapy?
Do you routinely prescribe vitamin D to reduce the risk of fall-related fractures in elderly patients regardless of their serum levels?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
When cinacalcet is used to treat hypercalcemia in primary hyperparathyroidism, does it also normalize low serum phosphorus levels?
As part of work up for hyperparathyroidism, what form of calcium replacement(dietary or supplements) would you recommend in a patient with a history of gastric bypass and multiple calcium containing kidney stones?
Do you recommend initiating zoledronic acid for osteoporosis at the time of hospitalization for a fracture?
What is the recommended duration of Burosumab therapy for treating X-linked hypophosphatemia and how is response to therapy monitored?
